TrumpRx.gov
On February 5, 2026, President Donald Trump officially unveiled TrumpRx.gov during a White House event, joined by key figures in his administration’s health policy team:
• Dr. Mehmet Oz, Administrator of the Centers for Medicare & Medicaid Services (CMS), who has brought his preventive medicine expertise and public communication skills to help design and promote a user-friendly platform.
• Robert F. Kennedy Jr., Secretary of Health and Human Services (HHS), who has championed the initiative as part of the broader “Make America Healthy Again” (MAHA) agenda, emphasizing transparency, reduced middleman influence, and immediate relief from chronic disease costs.
• Albert Bourla, CEO of Pfizer, whose company was the first major pharmaceutical manufacturer to partner with the administration and remains one of the largest contributors to the platform at launch.
This collaboration builds on a series of Most-Favored-Nation (MFN) pricing agreements that President Trump began securing in 2025, starting with Pfizer in September. Under these deals, participating drug companies agree to offer many of their medications to American patients at prices aligned with the lowest rates paid in other developed nations — often resulting in discounts of 50% or more (and in some cases significantly higher) off list prices.
TrumpRx.gov serves as the public-facing portal that makes these discounted prices accessible. At launch, the site features over 40 branded medications from the initial five participating companies: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer. Pfizer alone contributes more than 30 drugs, including treatments for autoimmune conditions, diabetes, and other chronic illnesses.